There are ongoing difficulties with clinic-genetic correlations in movement disorders (Gannamani et al., 2p21, Magrinelli. 2021). Cesaroni et al., illustrate the importance of defining a genetic diagnosis with atypical symptoms. They describe a patient with a rare intellectual disability syndrome related to a pathogenic variant in FOXP1. Together with the classical phenotype, they describe paroxysmal dystonia and discuss the potential pathogenic role of FOXP1 in the basal ganglia, which may lead to movement disorders in this population.In addition, Ando et al. describe the prevalence RFC1 mutation carriers in a large cohort of patients with ataxia, who had a younger age of onset than previously described, in comparison to more typical late-onset presentations (Cortese et al., 2019). As the causative role of intronic variants have been increasingly recognized as potentially common causes of genetic movement disorders, the inclusion of relevant intronic variants on gene panels and the assessment of repeat expansions are important to improve diagnosis (Beijer et al., 2013).More comprehensive tests, such as WES, are becoming more routine in the field of movement disorder as well. Zou et al. showed how WES allowed the identification of a new pathogenic variant in the PLA2G6 gene in two siblings allowing immediate management of the affect probands, and counseling for the family.Genetic counselling is a key principle of the management of rare neurogenetic disorders and this is particularly important in the fatal prion diseases. Appleby et al. in their review discuss the genetic associations in sporadic, acquired and genetic prion diseases and present the intricacies of genetic testing during life or at autopsy, in addition to the thorny ethical quandaries for testing of at-risk family members. They discuss the possibility of future treatments targeting the PRNP gene.Given the complexity of rare genetic disorders, there is increasing use of an interdisciplinary team-based approach, such as the Undiagnosed Disease Program (Mühlbӓck et al., 2023). In their paper, Huang et al. describe the important experience of the White Matter Rounds network, an international, collaborative platform where clinicians and scientists discuss challenging cases, promoting new understanding of these complex diseases and leveraging different expertise to aid in the diagnosis and facilitate research in white matter disorders leukodystrophies.There are understandable challenges in the design and implementation of clinical trials in rare neurological disorders. Videnovic et al highlight the lessons learned from clinical trials in pantothenate kinase-associated neurodegeneration, discussing successful strategies which can be applied to other rare and particularly metabolic movement disorders. They suggest multi-disciplinary engagement with experts and approaches concerning selection and recruitment of appropriate patients, trial endpoints and duration, special statistical considerations and the importance of regulatory feedback.Therefore, as genetic diagnosis become more relevant in the landscape of movement disorders, diagnostic and therapeutic approaches need to be reshaped to include new discoveries in clinical practice and maximize implementation of integrative resources from the clinical and research settings.
8 Authors
- AV
Aleksandar Videnovic
Department of Neurology, Massachusetts General Hospital and Harvard Medical School, United States
- HC
Helle C. V. Pfeiffer
Department of Child Neurology, Oslo University Hospital-Rikshospitalet, Norway
- AT
Anna Tylki-Szymańska
Department of Pediatrics, Nutrition and Metabolic Diseases, Children's Memorial Health Institute IPCZD, Poland
- EB
Elizabeth Berry-Kravis
Department of Pediatrics, Neurological Sciences, Anatomy and Cell Biology, Rush University Medical Center, United States
- FE
Fatih Ezgü
Department of Pediatrics, Gazi University Faculty of Medicine, Türkiye
- JG
Jitendra Ganju
Consultant to BridgeBio, United States
- AJ
Agnieszka Jurecka
CoA Therapeutics, Inc., A BridgeBio Company, United States
- AE
Anthony E. Lang
Department of Medicine (Neurology), Edmond J. Safra Program in Parkinson's Disease, and the Rossy Progressive Supranuclear Palsy Centre, Toronto Western Hospital, University of Toronto, Canada
8 Authors
- YZ
Yongyi Zou
Department of Medical Genetics, Jiangxi Maternal and Child Health Hospital, China
- HL
Haiyan Luo
Department of Medical Genetics, Jiangxi Maternal and Child Health Hospital, China
- HY
Huizhen Yuan
Department of Medical Genetics, Jiangxi Maternal and Child Health Hospital, China
- KX
Kang Xie
Department of Medical Genetics, Jiangxi Maternal and Child Health Hospital, China
- YY
Yan Yang
Department of Medical Genetics, Jiangxi Maternal and Child Health Hospital, China
- SH
Shuhui Huang
Department of Medical Genetics, Jiangxi Maternal and Child Health Hospital, China
- BY
Bicheng Yang
Department of Medical Genetics, Jiangxi Maternal and Child Health Hospital, China
- YL
Yanqiu Liu
Department of Medical Genetics, Jiangxi Maternal and Child Health Hospital, China
3,477 views
9 citations
